A5020698232- Breast Cancer Treatment Studies
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer, Stress, Anesthesia, and Immune Response
- Metastasis and carcinoma case studies
- Economic and Financial Impacts of Cancer
- Inflammatory mediators and NSAID effects
- Metabolism, Diabetes, and Cancer
- Pharmacogenetics and Drug Metabolism
- Cutaneous lymphoproliferative disorders research
- Colorectal Cancer Screening and Detection
University of New Mexico
2010-2024
New Mexico Cancer Center
2017
UNM Comprehensive Cancer Center
2010
Mayo Clinic
2002-2006
Biostatistical Consulting (United States)
2005-2006
Cancer Research And Biostatistics
2005
Abstract Purpose: In the adjuvant treatment of estrogen receptor (ER)–positive breast cancer, additional markers are needed to identify women at high risk for recurrence. Experimental Design: We examined association between ratio homeobox 13 (HOXB13) interleukin-17B (IL-17BR) expression and clinical outcomes relapse survival in with ER-positive cancer enrolled onto a North Central Cancer Treatment Group tamoxifen trial (NCCTG 89-30-52). Results: Tumor blocks were obtained from 211 256...
Abstract Obesity exerts adverse effects on breast cancer survival, but the means have not been fully elucidated. We evaluated obesity as a contributor to survival according tumor molecular subtypes in population-based case–cohort study using data from Surveillance Epidemiology and End Results (SEER) program. determined whether obese women were more likely be diagnosed with poor prognosis characteristics quantified contribution of survival. Hazard ratios (HRs) 95% confidence intervals (CI)...
Abstract Purpose: We examined the feasibility of using molecular characterization circulating tumor cells as a method for early detection breast cancer. Research Design: Women without prior history cancer who had abnormality detected on imaging followed by biopsy were enrolled in this study. Density gradient centrifugation and immunomagnetic capture used to enrich epithelial from ∼20 mL blood. Real-time reverse transcription-PCR was quantitate expression levels highly breast-specific genes,...
Abstract Background: Hispanic women in New Mexico (NM) are more likely than non-Hispanic to die of breast cancer–related causes. We determined whether survival differences between and might be attributable the method detection, an independent cancer prognostic factor previous studies. Methods: White diagnosed with invasive from 1995 through 2004 were identified NM Surveillance Epidemiology End Results (SEER) files (n = 5,067) matched Mammography Project records. Method detection was...
Introduction Differences in breast cancer survival by race and ethnicity are often assumed to be a fairly recent phenomenon, hypothesized have arisen due gaps receipt of screening or therapy. The emergence these differences calendar time implications for identification their origin. We sought determine whether arose tandem with the advent therapeutic advances. Materials methods A cohort women diagnosed invasive from 1975–2009 18 population-based registries were followed five-year...
Although Hispanic White (HW) females have a lower incidence of breast cancer than non-Hispanic (NHW) females, risk is unclear for HW after benign disease (BBD).
<div>AbstractIntroduction:<p>Although Hispanic White (HW) females have a lower incidence of breast cancer than non-Hispanic (NHW) females, risk is unclear for HW after benign disease (BBD).</p>Methods:<p>We compared BBD characteristics and subsequent among NHW in New Mexico using population-based collection biopsies (1996–2007). was categorized as nonproliferative (NPD), proliferative without atypia (PDWA), or atypical hyperplasia (AH). Breast assessed absolute (AR)...
<div>AbstractIntroduction:<p>Although Hispanic White (HW) females have a lower incidence of breast cancer than non-Hispanic (NHW) females, risk is unclear for HW after benign disease (BBD).</p>Methods:<p>We compared BBD characteristics and subsequent among NHW in New Mexico using population-based collection biopsies (1996–2007). was categorized as nonproliferative (NPD), proliferative without atypia (PDWA), or atypical hyperplasia (AH). Breast assessed absolute (AR)...
Abstract Introduction: Benign breast disease (BBD) is an important cancer (BC) risk factor, which may be classified as non-proliferative (NPD), proliferative without atypia (PDWA), or atypical hyperplasia (AH) for stratification. Data related to the frequency of specific types BBD and their relationship BC in Hispanic American population are limited. To address this knowledge gap, we compared associated among white (HW) non-Hispanic (NHW) New Mexico (NM). Methodology: A retrospective...
Abstract Background: Biomarkers expressed in benign or normal breast tissue may be important indicators of subsequent risk malignancy, but investigations identifying such have been few. Limited previous evidence suggests that loss expression several cancer tumor markers tissue, relative to contribute malignant progression. We examined implicated tumorigenesis among women who developed shortly after biopsy. Material and Methods: conducted a nested case-control study within population-based...